- Samsung Biologics reported FY 2025 revenue of KRW 4,557 billion, with Q4 revenue of KRW 1,286 billion, supported by full utilisation across Plants 1–4.
- The CDMO outlined a 2026 outlook of 15–20% revenue growth, alongside continued capacity expansion and a planned US manufacturing acquisition.
Samsung Biologics reported its financial results for the fourth quarter and full fiscal year 2025, citing stable performance amid global uncertainty. Q4 revenue reached KRW 1,286 billion and operating profit KRW 528 billion, while FY 2025 revenue totalled KRW 4,557 billion. The company attributed performance to consistent operations and full utilisation across Plants 1 through 3, with Plant 4 also fully utilised from the third quarter of 2025.
For the full year, operating profit rose to KRW 2,069 billion and EBITDA to KRW 2,439 billion, reflecting expanded project execution across its contract manufacturing network. “In 2025, Samsung Biologics delivered stable and resilient performance despite a highly uncertain global environment,” said John Rim, President and CEO, noting disciplined execution and strong demand.
During Q4 2025, the CDMO secured a KRW 1.1 trillion manufacturing agreement with a European pharmaceutical company, contributing to cumulative contract value exceeding USD 21 billion. Cumulative regulatory approvals reached 420, underscoring the company’s focus on quality and compliance. Samsung Biologics reaffirmed its position as a pure-play CDMO following an equity spin-off and confirmed that Plant 5 is expected to begin contributing revenue in 2026, supporting a projected 15–20% annual revenue growth outlook, excluding potential US acquisition contributions.
The company also outlined progress on infrastructure investments. In December 2025, it announced plans to acquire a US manufacturing site in Rockville, Maryland, comprising two cGMP plants with a combined 60 kL drug substance capacity, with closing expected in Q1 2026. Additional initiatives include preparations for a fully automated pre-filled syringe drug product line targeted to be cGMP-ready by 2027, continued development of Bio Campus III to support advanced conjugation, cell and gene therapies, and antibody vaccines, and ongoing ESG actions, including an ‘A’ Water Security rating from CDP.
